Last reviewed · How we verify
NCT04041037
The Management of Pilonidal Wounds With ACell MicroMatrix® and Cytal® Wound Matrix: A Case Series
trial testing Wound Sheet Matrix 2-Layer and Powder Urinary Bladder Matrix in Pilonidal Disease in 2 participants. Terminated before completion.
30 August 2019
Quick facts
| Lead sponsor | Integra LifeSciences Corporation |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 2 |
| Start date | 26 March 2019 |
| Primary completion | 30 August 2019 |
| Estimated completion | 5 November 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Wound Sheet Matrix 2-Layer and Powder Urinary Bladder Matrix
Conditions studied
- Pilonidal Disease — all drugs for Pilonidal Disease →
Sponsor
Integra LifeSciences Corporation — full company profile →
Who can join
18 and older, any sex, with Pilonidal Disease. Patients with the condition only — healthy volunteers not accepted.
Adverse events — posted to ClinicalTrials.gov
Time frame: 5 months. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Other adverse events (1 terms — click to expand)
| Reaction | System | All Participants |
|---|---|---|
| Bacterial Infection | Infections and infestations | — |
Data from ClinicalTrials.gov NCT04041037 adverse events section.
Sponsor's own description
A case series involving the concomitant use of MicroMatrix® and Cytal® Wound Matrix 2-Layer with standard of care negative pressure wound therapy (NPWT) during the management of pilonidal wound healing.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04041037
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pilonidal Disease
Currently open trials in the same condition.
- NCT07321704 — Effect of Antiseptic Irrigations With 0.05% Chlorhexidine Gluconate (Irrisept) Versus Normal Saline on Fasciocutaneous F · NA · recruiting
- NCT06406621 — Pilot Trial Assessing the Effectiveness of Laser Hair Depilation on Pilonidal Disease Recurrence in Patients With Darker · NA · recruiting
- NCT06286397 — Topical Anti-Androgens in Pilonidal Sinus Disease · Phase 2 · recruiting
- NCT06391307 — The Role of Mesenchymal Stem Cell and Exosome in Treating Pilonidal Sinus Disease in Children · NA · recruiting
- NCT03772873 — MIPE for Pilonidal Disease · active not recruiting
Other Integra LifeSciences Corporation trials
Trials by the same sponsor.
- NCT06760611 — Tissue Quality of Integra vs. BTM Treated Burns · withdrawn
- NCT06629506 — MicroMatrix® Flex in Tunneling Wounds · NA · completed
- NCT06453187 — A Modified Platform Trial of Multiple CAMPs for the Management of Diabetic Foot Ulcers and Venous Leg Ulcers · NA · enrolling by invitation
- NCT06276543 — Bactiseal Catheter Safety Registry Study · recruiting
- NCT06297187 — Cavitronic Ultrasonic Surgical Aspiration (CUSA) Women's Health Study · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04041037 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Integra LifeSciences Corporation
- Last refreshed: 20 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04041037.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing